PUBLISHER: The Business Research Company | PRODUCT CODE: 2133521
PUBLISHER: The Business Research Company | PRODUCT CODE: 2133521
The anti-obesity drugs refer to medications that are used to reduce or regulate a patient's weight. These drugs interfere with one of the body's basic functions, weight control, by affecting either appetite or calorie absorption. Dieting (a healthy diet and caloric restriction) and exercise continue to be the primary therapeutic approaches for people who are overweight or obese.
The main classes of drugs in anti-obesity are peripherally acting anti-obesity drugs and centrally acting anti-obesity drugs. Anti-obesity medications with a peripheral effect help people lose weight without affecting the brain or reducing appetite. They block pancreatic lipase and inhibit fat breakdown in the gastrointestinal tract, thereby reducing fat absorption through the intestine. The different types of drugs include prescription drugs (Rx) and OTC drugs and involve various medications such as monotherapies and polytherapy.
Tariffs have raised the cost of imported APIs used in anti-obesity drug manufacturing and formulation activities. These impacts are most significant in North America and Europe, where many metabolic drug manufacturers depend on global API supply networks. Increasing tariff-related input costs have placed pressure on production economics and pricing strategies for weight management therapies. This has affected procurement planning and market access decisions among pharmaceutical companies. However, tariffs are also encouraging domestic manufacturing of metabolic drugs, localized API production, and stronger regional pharmaceutical supply chains over the long term.
The antiobesity market research report is one of a series of new reports from The Business Research Company that provides antiobesity market statistics, including antiobesity industry global market size, regional shares, competitors with a antiobesity market share, detailed antiobesity market segments, market trends and opportunities, and any further data you may need to thrive in the antiobesity industry. This antiobesity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The antiobesity market size has grown strongly in recent years. It will grow from $4.13 billion in 2025 to $4.53 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to increasing global obesity rates, limited effectiveness of lifestyle-only interventions, availability of appetite suppressants, rising burden of metabolic disorders, physician-led weight management.
The antiobesity market size is expected to see strong growth in the next few years. It will grow to $6.61 billion in 2030 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to the increasing prevalence of diabetes and obesity, advancements in hormone-based drugs, expansion of reimbursement coverage, growing obesity awareness, and increasing demand for sustainable weight loss solutions. Major trends in the forecast period include the rapid adoption of GLP-1-based therapies, growing preference for prescription weight loss drugs, increasing use of combination anti-obesity therapies, greater focus on long-term weight management, and expanding access to obesity treatment.
The increasing prevalence of obesity is expected to drive the growth of the anti-obesity drugs market going forward. Obesity is a chronic metabolic condition characterized by excessive accumulation of body fat, which increases the risk of serious health complications, including diabetes, cardiovascular diseases, osteoarthritis, and certain cancers. The increasing prevalence of obesity is attributed to the growing consumption of ultra-processed foods that are high in sugars, unhealthy fats, and refined carbohydrates, along with sedentary lifestyles that limit physical activity. This rise in obesity prevalence is increasing the demand for effective anti-obesity medical interventions, supportive weight management therapies, and long-term treatment solutions to reduce associated health risks and enhance patient outcomes. For instance, in March 2024, according to the World Obesity Federation, a UK-based organization focused on obesity research and advocacy, 79% of adults with overweight and obesity and 88% of children with overweight and obesity are projected to be living in low- and middle-income countries by 2035. Therefore, the increasing prevalence of obesity is driving the growth of the anti-obesity drugs market.
Major companies operating in the antiobesity market are emphasizing product innovation and formulation, including dual glucose-dependent insulinotropic peptide receptor agonists, to deliver more effective weight loss, enhanced metabolic outcomes, and improved tolerability. These therapies utilize synergistic effects on appetite suppression, insulin sensitivity, and energy expenditure to achieve greater efficacy compared with earlier-generation GLP-1-only treatments. For instance, in December 2024, Eli Lilly, a US-based pharmaceutical company, received FDA approval for Zepbound (tirzepatide), making it the first and only prescription dual GIP/GLP-1 agonist approved for chronic weight management. Tirzepatide has demonstrated strong weight-loss efficacy, with participants in phase 3 trials achieving substantial reductions in body weight. With this new indication, Zepbound is expected to strengthen Lilly's leadership in the precision obesity therapy space, addressing the growing demand for long-acting, high-efficacy treatments.
In August 2023, Eli Lilly, a US-based pharmaceutical company, acquired Versanis Bio for an undisclosed amount. Through this acquisition, Eli Lilly aims to strengthen its antiobesity drug portfolio by incorporating Versanis Bio's innovative therapies targeting metabolic and weight-management pathways, supporting the development of next-generation treatments for obesity and related metabolic disorders. Versanis Bio is a US-based biotechnology company that specializes in developing novel therapeutics for obesity and metabolic diseases, with a strong track record in preclinical and early-stage clinical research.
Major companies operating in the antiobesity market are Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd.
North America was the largest region in the anti-obesity market in 2025. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the antiobesity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The anti-obesity market consists of sales of liraglutide, semaglutide, naltrexone-bupropion, and orlistat. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Antiobesity Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses antiobesity market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for antiobesity ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The antiobesity market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.